"Introduction
The ChAdOx1-S (Oxford-AstraZeneca), BNT162b2 (Pfizer-BioNTech) and CoronaVac (Sinovac) COVID-19-specific vaccines are among the most frequently used worldwide to protect against coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
A significant challenge has been vaccine uptake. More than three years after the emergence of COVID-19, nearly one-third of the global population is yet to receive a COVID-19 vaccine dose. A contributing factor is hesitancy resulting from concerns about the rapid development of vaccines and the potential for adverse events...
In this nested, prospective, cohort study among participants who received homologous 2-dose regimens of three different COVID-19-specific vaccines, we aimed to: (a) determine the incidence of AEFI [adverse events following immunization]; (b) compare AEFI by vaccine type, dose and country; (c) identify factors influencing the incidence of AEFI; and (d) assess the association between reactogenicity and vaccine antibody responses.
Materials and methods
Setting and participants: Participants were healthcare workers recruited in Australia and Brazil between March 2020 and April 2021 in the BRACE trial [NCT04327206] who had COVID-19 vaccine responses solicited...
Results
Of the 1302 participants who received homologous COVID-19 vaccines for the first two doses, 1219 (94%) completed questionnaires providing information on vaccine reactions after both vaccinations. Of these, 988 were in Brazil and 231 in Australia, with an age range of 18 to 73 years (median 41), and the majority (74%) were female...
In the seven days following first or second dose of COVID-19 vaccine, the incidence of any local reaction differed between vaccines (p < 0.001), and was higher in BNT162b2 vaccine recipients (111/151, 74%), compared with ChaAdOx1 (281/806, 35%; p < 0.001) or CoronaVac (43/262, 16%; p < 0.001) vaccine recipients...
Discussion
... Our finding that the incidence of systemic reactions was higher following first dose ChAdOx1-S compared with BNT162b2 or CoronaVac, and that the incidence of systemic reactions was higher following second dose BNT162b2 compared with ChAdOx1-S or CoronaVac, are consistent with other studies."
© 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.